Thus, the administration of bioactive molecules that mediate the L-PGDS–PGD2–DP1 axis may be a potential therapeutic strategy for regulating the clearance of cellular debris following brain injuries, such as ischemic stroke. This evidence concerns the gene PTGDS and ischemic stroke.